Redcare Pharmacy's Margin Reality Check Amid a Prescription Boom

Redcare Pharmacy's prescription sales soar 55%, but heavy investment slashes margin targets. All eyes are on the new CFO's strategy in the critical May 6 earnings report.

A powerful rally in Redcare Pharmacy shares, surging over 60% in a month to trade around €52, has captivated the market. This explosive move, fueled by a short squeeze that caught bearish investors off guard, masks a more complex financial story. While the company's prescription drug business is booming, significant capital investments are applying intense pressure on profitability, setting the stage for a critical earnings report.

The company's preliminary first-quarter figures underscore its dominant growth trajectory. Group revenue jumped 18.3% to €848 million, with the German market for prescription medications, known as Rx, soaring by 55%. Redcare commands a formidable two-thirds share of this online prescription market, a position further insulated by competitor Rossmann's stated refusal to enter the segment. Management has reaffirmed its full-year target of over €670 million in Rx sales for Germany, supported by its valid CardLink license and the integration of the GesundheitsID.

However, this impressive top-line performance exists alongside a stark margin squeeze. The company is in the midst of a major capacity expansion, constructing a new logistics center in Pilsen, Czech Republic, which will increase annual package handling capacity by 15 million units. This heavy capital expenditure has forced a recalibration of profit expectations. Redcare has already lowered its medium-term EBITDA margin target from over 8% to just above 5%. For the current year, the company is targeting an adjusted EBITDA margin of at least 2.5%.

This tension between growth and profitability will be the central focus when Redcare releases its full quarterly report on May 6. The presentation marks a key debut for the company's new Chief Financial Officer, Hendrik Krampe. Investors will be keen to hear the strategy from the former Amazon Europe finance director, who brings eleven years of experience from the e-commerce giant. The market will scrutinize whether the explosive Rx growth can translate into sustainable profits that justify the current high investment phase, which the board expects to continue until after 2027.

Regulatory developments may provide a structural tailwind. To address a projected €15.3 billion deficit in the statutory health insurance system by 2027, the German government is considering reforms. A key proposal would significantly increase prescription co-payments for patients, potentially raising them from the typical €5-€10 range to as much as €15. Analysts, including Felix Dennl of Bankhaus Metzler, believe higher out-of-pocket costs will drive price-sensitive customers toward cheaper online alternatives, a trend that would disproportionately benefit the market leader.

While the prescription segment thrives, Redcare faces mounting competition in over-the-counter (OTC) products. Aggressive moves by drugstore giants dm and Rossmann into online sales have prompted Redcare to cut its growth forecast for this segment to 8-10%. The impending launch of dm's "dm-med" platform in December 2025 adds to concerns over future market share erosion in the OTC space.

Despite the margin pressure, analyst sentiment remains partly optimistic. Jefferies has set a price target of €150 for the stock, citing the company's growing power in the e-prescription market. Yet, the long-term chart remains bruised, with the shares still down approximately 21% year-to-date. The upcoming report will deliver the hard facts. If the new CFO's profitability update disappoints, the recent spectacular share price recovery could prove fragile.